Design of patient rooms and automatic radioiodine-131 waste water management system for a thyroid cancer treatment ward: ‘Suandok model’

Vilasdechanon, Nonglak; Ua-apisitwong, Supoj; Chatnampet, K; Ekmahachai, Molrudee; Vilasdechanon, J.

doi:10.1088/0952-4746/34/3/699

Cited by 2 publications

(1 citation statement)

References 1 publication

(1 reference statement)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, a comprehensive therapeutic method for PTC involves surgery assisted by endocrinotherapy and radioactive I-131 treatment (22). Located on the epithelial cell membrane, NIS is a type of glycoprotein, whose genes are on the short arm of chromosome 19 (23). NIS carries iodine into cytoplasm using a sodium potassium pump, and is important for the maintenance of iodine uptake capacities of thyroids, while also participating in the synthesis of thyroid hormones (24).…”

Section: Discussionmentioning

confidence: 99%

Cell penetrating peptide of sodium-iodide symporter effect on the I-131 radiotherapy on thyroid cancer

Fan

Liang

Liu

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The aim of the present study was to clarify whether the cell penetrating peptide of sodium-iodide symporter (NIS) has an effect on the I-131 radiotherapy of thyroid cancer. Firstly, we combined the HIV-1 TAT peptide (a cell penetrating peptide, dTAT) and established a nanoparticle vector (dTAT NP) to study the delivery efficiency of this cell-penetrating strategy for tumor-targeted gene delivery. dTAT NP was transfected into cultured TPC-1 cells as a model to study the effects of I-131 radiotherapy on thyroid cancer. Reverse transcription-quantitative polymerase chain reaction and western blotting results showed that the mRNA and protein expression levels of NIS in the transfected TPC-1 cells were substantially higher than in the negative control cells. MTT and flow cytometric analyses demonstrated that the cell growth and apoptosis rates of the TPC-1 cells were significantly inhibited and activated, respectively, by treatment with dTAT NP. The results of DAPI staining showed that treatment with dTAT NP visibly increased the nuclear apoptosis rate of the TPC-1 cells. The effect of dTAT NP on TPC-1 cells was associated with the promotion of caspase-3 and downregulation of the PI3K/Akt signaling pathway. In summary, the present data provide a pre-clinical proof-of-concept for a novel gene delivery system that efficiently delivers NIS to the targeted cancer cells and presents a satisfactory efficacy. This approach may offer an effective strategy for improving thyroid cancer gene therapy.

show abstract

Section: Discussionmentioning

confidence: 99%